A comprehensive clinical and owner-facing guide to recognising, diagnosing, and managing canine osteoarthritis â improving quality of life at every stage.
Canine arthritis â most commonly osteoarthritis (OA) â is a progressive, degenerative joint disease characterised by the breakdown of cartilage within one or more joints. As cartilage erodes, bone surfaces come into closer contact, leading to inflammation, pain, and reduced mobility.
OA is not a normal part of ageing, but it becomes increasingly prevalent as dogs grow older. It can affect any joint, though the hips, elbows, stifles (knees), and spine are most commonly impacted. The condition is chronic and currently incurable, but its progression can be slowed and its symptoms significantly managed.
Arthritis causes chronic pain that dogs often mask instinctively. By the time owners notice behavioural changes, significant joint damage may already exist â making early recognition and proactive management essential.
Idiopathic degeneration of cartilage, typically associated with age, breed predisposition, or chronic wear. The most common form seen in clinical practice.
Develops following joint injury, developmental disorders (e.g. hip dysplasia, elbow dysplasia, OCD), or infectious joint disease. Can occur in younger animals.
Inflammatory arthritis driven by autoimmune processes. Less common but important to differentiate from OA as treatment pathways differ significantly.
Bacterial infection within the joint space, typically arising from penetrating wounds, surgery, or haematogenous spread. Requires urgent antimicrobial intervention.
Symptoms vary by severity and affected joint. Look for changes in behaviour, gait, posture, and daily activity patterns.
Difficulty rising after sleep or prolonged rest, improving with gentle movement. Often most noticeable first thing in the morning.
Slight favouring of one or more limbs, particularly after exercise. May be intermittent and easy to dismiss initially.
Less enthusiasm for walks, play, or jumping. Dog may seem 'slowing down' â often attributed incorrectly to normal ageing.
Bunny-hopping, paddling, or short-striding. Changes in how the dog distributes weight when standing or moving.
Increased irritability, reluctance to be touched in affected areas, aggression when handled. Withdrawal from social interaction.
Hunched back, lowered head carriage, or tucked abdomen. Difficulty adopting comfortable positions when resting.
Noticeable reduction in muscle mass over affected limbs due to disuse. Most apparent over the hindquarters in hip OA.
Palpable effusion or periarticular swelling. Increased local warmth indicating active inflammation in the joint capsule.
Restlessness at night, frequent repositioning, vocalisation while sleeping, or reluctance to lie down. Indicates significant chronic pain.
Accurate diagnosis combines owner history, physical examination findings, and diagnostic imaging. No single test confirms OA.
Duration of signs, onset pattern, exercise tolerance, behaviour changes, previous joint injuries, and breed-specific predispositions. Owner-completed questionnaires (e.g. CBPI, Helsinki Chronic Pain Index) provide structured data.
Gait analysis at walk and trot, limb palpation for symmetry, range-of-motion assessment, joint manipulation for pain, crepitus, and effusion. Neurological screening to rule out myelopathy.
Use validated scales (e.g. Colorado State University Canine Acute Pain Scale, Canine Brief Pain Inventory) to quantify severity and establish a baseline for monitoring treatment response.
Objective gait analysis providing quantitative weight-bearing data. Useful for confirming subtle lameness and tracking treatment outcomes in specialist settings.
First-line imaging. OA changes include periarticular osteophytosis, subchondral sclerosis, joint space narrowing, and soft tissue swelling. General anaesthesia or heavy sedation improves positioning and diagnostic quality.
Useful for assessing soft tissue structures, joint effusion, and periarticular changes. Can guide arthrocentesis when synovial fluid analysis is indicated.
Advanced imaging for complex cases â particularly elbow OA, spinal disease, or where surgical planning is required. MRI provides superior soft tissue detail and cartilage assessment.
Arthrocentesis to differentiate OA (non-inflammatory) from immune-mediated or septic arthritis. OA fluid is typically clear, viscous, with low nucleated cell count (<3,000 cells/ΞL).
| Grade | Severity | Radiographic Changes | Clinical Signs | Management Priority |
|---|---|---|---|---|
| Grade 1 | Mild | Minimal periarticular osteophytes; possible joint space narrowing | Subtle stiffness; intermittent lameness post-exercise | Lifestyle modification; weight management; monitoring |
| Grade 2 | Moderate | Obvious osteophytes; subchondral sclerosis; moderate joint space reduction | Consistent lameness; activity limitation; behavioural changes | Multimodal analgesia; physiotherapy; nutraceuticals |
| Grade 3 | Severe | Extensive osteophytes; marked joint space loss; joint remodelling | Persistent pain at rest; significant muscle atrophy; mobility impairment | Intensive medical management; specialist referral; surgical assessment |
| Grade 4 | End-stage | Complete or near-complete joint space loss; eburnation; marked deformity | Severe chronic pain; minimal functional ability; pronounced welfare impact | Surgical intervention or palliative care; quality of life assessment |
Arthritis can affect any breed at any age, but certain factors significantly increase a dog's likelihood of developing the condition.
Labradors, German Shepherds, Golden Retrievers, Rottweilers, and Bernese Mountain Dogs are disproportionately affected due to joint load and genetic predisposition.
Being overweight is the single most modifiable risk factor. Excess body weight dramatically accelerates cartilage degradation and increases mechanical joint stress.
Hip dysplasia, elbow dysplasia, and osteochondrosis dissecans (OCD) create abnormal joint mechanics that accelerate degenerative changes from a young age.
Prevalence increases markedly after 7 years. By age 10, the majority of medium and large breed dogs show some degree of joint degeneration on imaging.
Cruciate ligament rupture, fractures involving joint surfaces, and dislocation significantly increase the risk of secondary OA in the affected joint.
Sustained high-impact activity without adequate recovery, particularly in working and sporting dogs, can accelerate joint wear over time.
Effective OA management is multimodal. No single treatment is sufficient; the best outcomes come from combining complementary strategies tailored to each patient.
Non-steroidal anti-inflammatory drugs (e.g. carprofen, meloxicam, robenacoxib, grapiprant) are the cornerstone of OA analgesia. Provide both anti-inflammatory and analgesic effects. Require regular monitoring of renal and hepatic function.
Strong EvidenceMonoclonal antibodies targeting nerve growth factor â a key mediator of OA pain. Monthly injection. Represents a significant advance for cases where NSAIDs are contraindicated or insufficient.
Strong EvidenceAdjunctive neuropathic pain agents. Useful in chronic, central sensitisation cases or as part of a multimodal protocol where NSAIDs alone are insufficient.
Moderate EvidenceOpioid-like analgesic. Bioavailability and efficacy in dogs is debated; clinical response is variable. Often used as a short-term adjunct rather than long-term monotherapy.
Moderate EvidencePotent anti-inflammatory effect but significant long-term side effects limit chronic use. Reserved for inflammatory flares or cases with immune-mediated component. Should not be combined with NSAIDs.
Use SelectivelyCorticosteroid or hyaluronic acid injections directly into the joint space. Useful for localised disease or when systemic medications are contraindicated. Effects typically temporary.
Moderate EvidenceTargeted exercise programmes to maintain muscle mass, improve joint stability, and preserve range of motion. Conducted by qualified veterinary physiotherapists. Essential for long-term joint health.
Strong EvidenceUnderwater treadmill or swimming allows low-impact exercise that maintains cardiovascular fitness and muscle conditioning without loading painful joints. Highly effective for post-surgical rehabilitation and chronic OA.
Strong EvidenceClass IV laser therapy reduces local inflammation, promotes tissue repair, and provides analgesia. Often used as part of a multimodal programme. Requires multiple sessions for sustained benefit.
Moderate EvidenceTranscutaneous electrical nerve stimulation and neuromuscular electrical stimulation for analgesia and muscle activation in atrophied limbs. Adjunctive use alongside physiotherapy programmes.
Moderate EvidenceVeterinary acupuncture may provide analgesia via endogenous opioid release and neurological mechanisms. Evidence base growing; considered adjunctive in an integrative pain management programme.
Emerging EvidenceAcoustic waves applied to affected joints and surrounding tissues to stimulate healing responses and reduce pain. Used particularly for hip OA and calcifying tendinopathies.
Emerging EvidenceStructural components of cartilage. Widely used as nutraceuticals; thought to support cartilage integrity and reduce inflammation. Clinical evidence is variable but generally considered safe and potentially beneficial.
Moderate EvidenceMarine-sourced omega-3s (fish oil) have anti-inflammatory properties and may reduce the need for NSAIDs. Well-tolerated with a favourable safety profile; best sourced from reputable veterinary products.
Good EvidenceContains a range of bioactive compounds including omega-3s, glucosamine, chondroitin, and antioxidants. Some clinical trials show meaningful reduction in lameness scores.
Moderate EvidenceSeveral veterinary prescription diets are formulated with high levels of omega-3s, antioxidants, and joint-supporting nutrients. Can simplify supplementation and aid in weight management simultaneously.
Moderate EvidenceAnti-inflammatory properties proposed through NF-ΚB pathway inhibition. Bioavailability in dogs is a limiting factor; formulation matters significantly. Emerging area of veterinary interest.
Emerging EvidenceProposed mechanism via oral tolerance induction, reducing immune-mediated cartilage degradation. Some studies show reduction in lameness; not as established as omega-3s or glucosamine.
Emerging EvidenceGold standard surgical treatment for severe hip OA. Replaces the entire hip joint with a prosthesis, eliminating arthritis pain from that joint. High success rate in appropriate candidates; requires specialist referral.
Strong EvidenceRemoves the femoral head to eliminate bone-on-bone contact. Reliable salvage procedure for hip OA; outcomes better in smaller dogs. Less costly than THR; remains a viable option when THR is not feasible.
Strong EvidenceMinimally invasive joint examination and intervention. Useful for debridement of osteochondral fragments, synovial biopsy, and joint lavage in early-to-moderate OA. Less invasive than open arthrotomy.
Moderate EvidenceDefinitive surgical treatment for cranial cruciate ligament rupture â a major cause of stifle OA. Stabilises the joint biomechanically and significantly reduces secondary arthritis progression.
Strong EvidenceSurgical fusion of severely affected joints (commonly carpus, tarsus, or digits). Eliminates pain by preventing movement; appropriate for end-stage disease in distal joints where prosthetic options are limited.
Salvage ProcedureAutologous or allogeneic mesenchymal stem cells injected intra-articularly. Proposed anti-inflammatory and regenerative effects. Promising early results; requires further large-scale controlled trials to establish efficacy.
Emerging EvidenceAchieving and maintaining healthy body weight is arguably the single most impactful intervention in OA management. Studies show that weight loss alone can produce clinically significant improvements in lameness scores.
Strong EvidenceRegular, low-impact, consistent exercise on even terrain. Short, frequent walks rather than infrequent intense sessions. Swimming when possible. Avoid sudden changes in exercise intensity.
Strong EvidenceRamps instead of stairs, raised food and water bowls, non-slip flooring, orthopaedic bedding, limiting jumping, and providing warm sleeping areas. Reduces daily pain burden significantly.
Highly RecommendedApplication of gentle warmth to affected joints before exercise can reduce stiffness and improve comfort. Particularly useful in cold weather or for morning stiffness. Use with care to avoid burns.
Moderate EvidenceHarnesses, slings, and mobility aids for dogs with severe disease. Orthotic braces for specific joint support. Helpful for maintaining independence and facilitating exercise in later stages.
Supportive CareMental stimulation through scent work, puzzle feeders, and calm social interaction helps maintain quality of life when physical activity is limited. Prevents boredom and depression associated with chronic pain.
Quality of LifeAdvanced clinical guidance, monitoring frameworks, and treatment considerations for the veterinary team.
Use objective, repeatable tools to assess and track OA severity over time.
For dogs on chronic NSAID therapy, implement structured monitoring:
Ensure thorough orthopaedic and neurological workup to exclude:
Critical combinations to avoid in OA management:
Consider specialist referral in the following circumstances:
Improving treatment compliance and long-term outcomes:
Your daily actions have a profound impact on your dog's comfort and quality of life. Here's how to make a meaningful difference.
Even a 10â15% reduction in body weight can meaningfully reduce pain and improve mobility. Ask your vet about a target weight and appropriate diet.
Memory foam or orthopaedic mattresses reduce joint pressure during rest. Keep your dog warm in cold weather â cold worsens joint stiffness.
Install ramps for access to vehicles, sofas, or beds. Use rubber-backed mats or carpet runners on slippery floors to prevent slipping.
Little and often is better than sporadic intense walks. Aim for short, regular walks on flat, even terrain. Avoid jumping and sudden direction changes.
If you're concerned about your dog's medication, speak to your vet before making any changes. Abrupt discontinuation can cause rapid deterioration in comfort.
Record how your dog moves, sleeps, and behaves daily. Note good and bad days. This invaluable information helps your vet fine-tune treatment.
Regular check-ups are essential, especially for dogs on NSAIDs. Blood and urine tests detect side effects before they become serious.
Contact your vet promptly if you notice vomiting, diarrhoea, reduced appetite, increased thirst, or changes in urine colour or volume.
Ibuprofen, paracetamol (acetaminophen), naproxen, and aspirin are toxic to dogs. Even small doses can cause life-threatening organ damage. Always consult your vet.
Have honest conversations with your vet about your dog's wellbeing. Quality of life scales can help you assess when management is sufficient and when further decisions may be needed.